HT007 Inhibitors
HT007 Inhibitors influence a variety of biochemical and cellular pathways to exert their inhibitory effect on HT007. Rapamycin, by forming a complex with FKBP12, inhibits mTOR, potentially affecting HT007 if its activity is associated with mTOR-regulated pathways. Similarly, LY294002 and Wortmannin directly target PI3K, leading to decreased phosphorylation of AKT, which can diminish HT007 activity if it is AKT-dependent. Triciribine, by inhibiting AKT activation, can also reduce HT007 function if HT007 relies on AKT for its activity.
Furthermore, U0126 and PD98059 disrupt the MAPK/ERK pathway, potentially leading to reduced HT007 function if it depends on ERK for its activity. SP600125 and SB203580 inhibit JNK and p38 MAPK, respectively, which can lead to decreased HT007 activity if HT007 operates within these pathways.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If HT007 is negatively regulated by proteasomal degradation, bortezomib can lead to increased levels of HT007, but its activity might be reduced if it requires regular cycling through degradation and resynthesis for proper functioning. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, among others. If HT007 activity is modulated by RAF/MEK/ERK signaling, inhibition of this pathway by sorafenib would lead to a reduction in HT007 function. | ||||||